Bayer Proposes $7.25 Billion Settlement as Supreme Court Case Looms
Finn's Take· TL;DR- Bayer proposes $7.25 billion settlement covering 125,000+ Roundup cancer lawsuits, with payments spanning 21 years.
- Supreme Court will hear federal preemption case in April that could invalidate state-level failure-to-warn claims against Bayer.
- Settlement hedges legal risk regardless of Supreme Court outcome, protecting both plaintiffs and company from worst-case scenarios.
Massive Settlement Amid Legal Uncertainty
Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7.25 billion settlement Tuesday to resolve thousands of US lawsuits alleging the company failed to warn people that its popular weedkiller Roundup could cause cancer. The agreement would create a fund to pay people exposed to Roundup who later developed non-Hodgkin lymphoma, with payments spread over 21 years.
More than 125,000 plaintiffs have lodged legal claims over Roundup since 2015, according to the settlement documents. The company has paid about $11 billion to settle nearly 100,000 Roundup lawsuits, with roughly 61,000 still pending, according to a website that tracks the litigation. This latest proposal would address most remaining cases while covering future claims from people exposed before Tuesday's filing.
The settlement structure varies based on exposure patterns and illness severity. An agricultural, industrial or turf worker exposed at length to Roundup would receive an average of $165,000 if they were diagnosed with an aggressive form of the illness while younger than age 60, according to the proposed settlement.
Supreme Court Case Changes Everything
The proposed settlement comes as the US Supreme Court is preparing to hear arguments in April on Bayer's assertion that the US Environmental Protection Agency's approval of Roundup without a cancer warning should invalidate claims filed in state courts. The Supreme Court noted in a docket entry that a hearing on the case is scheduled for April 27.
The case centers on federal preemption—whether EPA approval of Roundup's labeling without cancer warnings should block state-level failure-to-warn lawsuits. Under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), the EPA must review and approve all pesticide labeling. The EPA has repeatedly declined to require a cancer warning for glyphosate—and has in fact rejected such efforts.
The Trump administration is siding with Bayer on the issue, and encouraged the Supreme Court to hear the case. This reverses the Biden administration's position and creates a powerful ally for Bayer's legal strategy.
Strategic Risk Management
The settlement proposal functions as insurance against either outcome from the high court. Patients would be assured of receiving settlement money even if the Supreme Court rules in Bayer's favor. And Bayer would be protected from potentially larger costs if the high court rules against it.
Germany-based Bayer, which acquired Roundup maker Monsanto in 2018, disputes the assertion that Roundup's key ingredient, glyphosate, can cause non-Hodgkin lymphoma. But the company has warned that mounting legal costs are threatening its ability to continue selling the product in US agricultural markets. "Litigation uncertainly has plagued the company for years, and this settlement gives the company a road to closure," Bayer CEO Bill Anderson said Tuesday.
Recent jury verdicts have created financial pressure, with 13 verdicts for Bayer and 11 for plaintiffs, including a $2.1 billion award by a Georgia jury last year. The company's shares rose around 7% after it announced the settlement proposal Tuesday.
The Path Forward
The proposed settlement was filed in St. Louis Circuit Court in Missouri, home to Bayer's North America crop science division and the state where many of the lawsuits have been brought. The settlement still needs the court's approval. If too many plaintiffs opt out of the proposed settlement, Bayer said it reserves the right to cancel it. But Bayer did not specify how many opt-outs would have to occur.
The Supreme Court decision will likely determine whether this settlement becomes the final chapter in Roundup litigation or merely another expensive Band-Aid. A ruling in Bayer's favor would effectively end future lawsuits, making the settlement a hedge against uncertainty. A ruling against Bayer could open floodgates to even costlier litigation, making this $7.25 billion look like a bargain.
For the thousands of people claiming Roundup caused their cancer, the settlement offers certainty in an uncertain legal landscape. For Bayer, it represents a calculated gamble—pay now to limit potentially catastrophic losses later, regardless of how the nation's highest court rules on one of the most significant product liability cases in decades.